In the ever-evolving pharmaceutical landscape, Pfizer (NYSE: PFE) is a key player, with its stock forecast garnering significant interest from investors and analysts alike. Heading into 2024 and beyond, the consensus tilts towards a cautiously optimistic outlook for Pfizer’s stock. This optimism is underpinned by the company’s strong product lineup, including vital pharmaceuticals and promising new treatments and vaccines. While analysts offer varied price targets, they anticipate potential growth in Pfizer’s stock value.
However, investors should note the industry’s sensitivity to regulatory shifts, competitive dynamics, and broader economic factors, which can influence stock trajectories. As we delve deeper into the details of Pfizer’s financial and market position, this article will provide a comprehensive analysis of the factors influencing Pfizer’s stock forecast and future forecasts about PFE stock price. This will offer insights to guide investors in making informed decisions in the dynamic world of pharmaceutical investing.
The article covers the following subjects:
Highlights and Key Points: (PFE) Pfizer Stock Price Forecast 2024-2030
- Current price: $28.72 as of today, 30.08.2024
- WalletInvestor predicts that Pfizer stock will fluctuate in a sideways channel in 2024, ranging from $27.076 to $28.207. The price is expected to hit around $28.098 by year-end.
- In 2025, WalletInvestor anticipates a slight decline in Pfizer stock. The forecast varies from $23.837 to $28.105, with a level of $24.897 expected at the end of the year.
- In the long term, forecasts vary significantly. CoinPriceForecast expects strong growth, suggesting that Pfizer stock may reach $38.18 by 2028. At the same time, WalletInvestor predicts a possible decline to at least $15.164.
PFE Stock Price Today Coming Days and Week
When forecasting Pfizer’s stock price in the short term, consider recent company news, particularly related to drug developments or regulatory approvals. Economic conditions affecting the healthcare sector, such as policy changes or healthcare spending trends, are also crucial. Keep an eye on Pfizer’s earnings reports and any announcements about partnerships or significant research outcomes. Market sentiment influenced by these factors, along with technical analysis using tools like Moving Averages and RSI, will help predict Pfizer’s stock movements in the coming days and weeks.
Get access to a demo account on an easy-to-use Forex platform without registration
Pfizer Price in 2024: Forecasts From Experts
Let’s take a look at expert forecasts for the PFE rate in 2024.
WalletInvestor
Price range in 2024: $27.076-28.207 (as of August 18 2024)
Walletinvestor has updated its Pfizer stock forecast for 2024. The new data suggest that the price will range from $27.076 to $28.207. A long sideways trend is projected, with the price following an unstable trajectory throughout the year. Although the decline has somewhat slowed, Pfizer has not yet managed to break the negative trend.
| Month | Opening, $ | Closing, $ | Minimum, $ | Maximum, $ |
|---|---|---|---|---|
| September | 27.993 | 27.304 | 27.304 | 27.993 |
| October | 27.272 | 27.298 | 27.076 | 27.321 |
| November | 27.357 | 27.902 | 27.357 | 27.902 |
| December | 27.963 | 28.098 | 27.963 | 28.207 |
CoinPriceForecast
Price range in 2024: $28.91-30.10 (as of August 18 2024)
According to CoinPriceForecast, Pfizer stock opened in 2024 at $28.91. The company’s shares are currently trading at $28.29, a slight 2% decline since the beginning of the year. However, forecasts provide a positive outlook: the share price is expected to reach $30.10 by the end of 2024, showing annual growth of 4%. This means the price may grow 6% from the current levels to the end of the year, which confirms the potential for recovery and confidence in the company.
| Year | Year-end, $ |
|---|---|
| 2024 | 30.10 |
PandaForecast
Price range in 2024: $27.14-30.73 (as of August 18 2024)
PandaForecast anticipates moderate positive trends for the rest of the year. In September, Pfizer’s average price will be $27.71, with a minimum of $27.14 and a maximum of $28.36. October will show a rise in the stock price: the average value will reach $29.63, with a possible maximum of $30.73, which indicates the strengthening of the company’s position. November will bring a minor correction, with the price expected to range from $28.58 to $30.45 and an average price of $29.29. December’s trends will remain stable, with an average of $29.21 and a maximum of $29.79. Overall, these forecasts indicate a gradual recovery of Pfizer shares with the possibility of reaching new highs by the end of the year.
| Month | Average price, $ | Minimum, $ | Maximum, $ |
|---|---|---|---|
| September | 27.71 | 27.14 | 28.36 |
| October | 29.63 | 27.82 | 30.73 |
| November | 29.29 | 28.58 | 30.45 |
| December | 29.21 | 28.13 | 29.79 |
Pfizer Stock Technical Analysis
Various timeframes and tools can be used in Pfizer stock technical analysis to assess market trends and determine optimal entry/exit points. Daily and weekly charts are suitable for short-term analysis as they help identify short-term fluctuations and trends. The useful toolkit includes moving averages (MA), which help identify the trend direction, and the relative strength indicator (RSI), which determines the overbought/oversold levels.
We will use monthly charts for long-term analysis to identify established trends and critical support/resistance levels efficiently. The MACD indicator, used to measure the trend strength, and Fibonacci ratios, which spot potential correction and extension levels, will be helpful in this context. We will also pay attention to chart patterns, such as triangles and head and shoulders, that can signal eventual trend reversals. These tools and patterns allow us to predict stock movements more accurately and make better-informed investment decisions.
blog
Promo code
#PFE Stock Forecast For Next Three Months
Pfizer’s Stock technical analysis for the next three months reveals a few key aspects. The RSI readings are at 39.32 on the daily chart, suggesting the asset is oversold and may grow in the short term despite the current downtrend.
Moving averages (SMA) are below the exponential moving average (EMA) and above the price, indicating a bearish trajectory. A failure to consolidate above resistance at $30 and a reversal to the downside confirm that signal.
The MACD shows the MACD line is at -0.1553, and the signal line is at 0.0696, pointing to a bearish trend and eventual additional losses in the short term.
Two false breakouts have occurred at support of $25.70, indicating the level’s potential instability. The price may vary from $25.70 to $30 in the next three months. The downtrend may continue to lower support levels unless the price breaks above resistance at $30 and consolidates higher.
Long-Term Pfizer Shares Technical Analysis for 2024
The long-term technical analysis of Pfizer stock for 2024, performed on the weekly time frame, has shown several key signals and trends. The relative strength index is at 47, showing that after reaching the low on December 24, 2023, the RSI value has gradually increased. This indicates a potential recovery and gradual improvement in market conditions.
The chart shows the moving averages (EMA and SMA), converging and slightly above the current stock price. This creates a slant to the downside, but their proximity to the price may signal a possible trend reversal.
The MACD indicator also shows a weakly expressed bullish signal: the MACD line at 0.11 and the signal line at 0.10 indicate a minimum divergence, which may suggest an emerging uptrend, but without clear signals of a substantial change.
In the medium term, the stock has been trending up since April 2024, with each new low being higher than the previous one. The price moves in an ascending channel, regularly bouncing off the resistance and support lines. This indicates a sustainable bullish trend with possible corrections as new resistance levels are reached. Thus, the long-term outlook for Pfizer stock looks positive, with potential for continued growth within the ascending channel.
| Month | Pfizer Inc. (#PFE) projected values | |
|---|---|---|
| Minimum, $ | Maximum, $ | |
| September | 26.14 | 28.16 |
| October | 26.82 | 30.53 |
| November | 27.58 | 30.25 |
| December | 27.13 | 29.60 |
Long-term trading plan for Pfizer Inc. (#PFE)
It is important to set both short-term and long-term targets to create an effective long-term trading plan for Pfizer Inc. (#PFE) stock.
Assessing current technical indicators and market conditions will help us identify target levels and strategies.
Over the next three months, focus on spotting short-term trends and possible corrections:
- Resistance level: $30.00. The price is expected to tend to that level, with possible breakouts and consolidation.
- Support level: $25.70. The key level for identifying potential false breakouts or consolidation.
- Target range: $27.00-$30.00. Keep an eye on price moves within that range to buy on pullbacks and sell at resistance levels.
The yearly scenario plan must consider long-term trends and strategic positioning:
- Long-term resistance level: $38.00. That’s a projected growth limit.
- Long-term support level: $25.00. Important level for hedging against large corrections.
- Target range: $32.00-$38.00. It is recommended to hold stock in this range, using support and resistance levels to make trading decisions.
This plan will allow you to manage positions and adapt to market conditions effectively.
Pfizer Price Forecast for 2025
Let’s take a look at expert forecasts for the PFE rate in 2025.
WalletInvestor
Price range in 2025: $23.837-28.105 (as of August 18 2024)
According to Walletinvestor, a mixed trajectory is projected for Pfizer shares in 2025, with slight rises and falls. Some strengthening is expected at the beginning of the year, but a downward correction with short-term pullbacks to lower values may occur by the middle of the year. Investors can expect the stock to move within a narrow range with minor fluctuations. Towards the end of the year, the price may stabilize, remaining relatively low, with rare attempts to grow. In general, despite the volatility, the stock tends to slow down the decline, which leaves the possibility of a potential recovery in the future.
| Month | Opening, $ | Closing, $ | Minimum, $ | Maximum, $ |
|---|---|---|---|---|
| January | 28.105 | 26.480 | 26.477 | 28.105 |
| February | 26.344 | 25.631 | 25.623 | 26.344 |
| March | 25.503 | 26.047 | 25.411 | 26.047 |
| April | 26.058 | 25.606 | 25.594 | 26.111 |
| May | 25.557 | 25.581 | 25.516 | 25.619 |
| June | 25.494 | 24.738 | 24.690 | 25.494 |
| July | 24.752 | 25.287 | 24.752 | 25.325 |
| August | 25.333 | 24.927 | 24.913 | 25.333 |
| September | 24.802 | 24.077 | 24.077 | 24.802 |
| October | 24.074 | 24.110 | 23.837 | 24.110 |
| November | 24.119 | 24.632 | 24.119 | 24.632 |
| December | 24.697 | 24.897 | 24.697 | 24.977 |
CoinPriceForecast
Price range in 2025: $31.12-31.61 (as of August 18 2024)
CoinPriceForecast‘s outlook for Pfizer stock in 2025 suggests a further strengthening of the company’s positions. The stock price may hit around $31.12 by mid-year, indicating steady growth.
The positive trend is expected to continue by the end of the year, with the stock reaching $31.61. This indicates a possible recovery of investor interest and a gradual improvement in the company’s financial performance.
| Year | Mid-Year, $ | Year-end, $ |
|---|---|---|
| 2025 | 31.12 | 31.61 |
PandaForecast
Price range in 2025: $26.46-40.15 (as of August 18 2024)
PandaForecast anticipates sustained growth of Pfizer stock throughout 2025. The price will stabilize in January after fluctuating, ranging from $26.46 to $29.28. February and March will see a significant increase, with highs above $30, finally reaching around $32.94. The trend will continue in the second quarter, with April and May promising new highs of $34.13 and $34.94, respectively. The stock may rise to $37.03 in July and $36.37 in August. Despite some fluctuations in the autumn, prices will remain at high levels, with a possible strengthening in November. The stock price is forecast to rise significantly by December, with a high of around $40.15, reflecting the prospects for further growth and confidence in the company’s future.
| Month | Average price, $ | Minimum, $ | Maximum, $ |
|---|---|---|---|
| January | 28.00 | 26.46 | 29.28 |
| February | 29.36 | 28.73 | 30.84 |
| March | 31.63 | 30.44 | 32.94 |
| April | 32.00 | 30.51 | 34.13 |
| May | 33.04 | 31.88 | 34.94 |
| June | 33.66 | 32.54 | 34.82 |
| July | 34.57 | 32.80 | 37.03 |
| August | 35.35 | 32.93 | 36.37 |
| September | 34.91 | 33.21 | 36.82 |
| October | 34.12 | 31.94 | 35.32 |
| November | 36.42 | 34.78 | 38.52 |
| December | 38.13 | 36.34 | 40.15 |
Pfizer Price Forecast for 2026
Let’s take a look at expert forecasts for the PFE rate in 2026.
WalletInvestor
Price range in 2026: $20.601-24.868 (as of August 18 2024)
According to Walletinvestor‘s updated data, Pfizer shares will probably continue trading sideways, suggesting price instability. The stock is forecast to start the year at around $24.841 in January but gradually decline over the next few months, reaching $21.487 by October.
Then, a slight recovery is expected, but the stock will unlikely return to higher levels before the end of the year, closing at around $21.633. Fluctuations throughout the year may be due to expectations of important news or events that could majorly impact the market.
| Month | Opening, $ | Closing, $ | Minimum, $ | Maximum, $ |
|---|---|---|---|---|
| January | 24.841 | 23.304 | 23.304 | 24.868 |
| February | 23.155 | 22.449 | 22.442 | 23.155 |
| March | 22.311 | 22.808 | 22.176 | 22.808 |
| April | 22.849 | 22.341 | 22.341 | 22.877 |
| May | 22.376 | 22.367 | 22.289 | 22.385 |
| June | 22.292 | 21.500 | 21.465 | 22.292 |
| July | 21.541 | 22.103 | 21.524 | 22.103 |
| August | 22.073 | 21.612 | 21.612 | 22.096 |
| September | 21.576 | 20.879 | 20.879 | 21.576 |
| October | 20.813 | 20.862 | 20.601 | 20.862 |
| November | 20.874 | 21.429 | 20.874 | 21.429 |
| December | 21.456 | 21.633 | 21.456 | 21.746 |
CoinPriceForecast
Price range in 2026: $32.50-34.59 (as of August 18 2024)
CoinPriceForecast anticipates positive trends for Pfizer stock in 2026. Moderate growth is expected at the beginning of the year, with the stock potentially reaching around $32.50 by mid-year. The second half of the year promises continued growth, with a potential increase to $34.59 by year-end. This positive trajectory indicates the recovery and strengthening of the company’s position, which may be due to improved financial performance or positive news.
The overall trend indicates a confident recovery and stable strengthening of Pfizer shares throughout the year.
| Year | Mid-Year, $ | Year-end, $ |
|---|---|---|
| 2026 | 32.50 | 34.59 |
PandaForecast
Price range in 2026: $32.01-43.67 (as of August 18 2024)
According to PandaForecast, Pfizer stock will likely experience significant volatility in 2026. Steady growth is expected at the beginning of the year, with the average price reaching $40 in February. However, there may be some small fluctuations in March and April, with highs close to $42. The stock may decline slightly in the middle of the year, especially in May and June, but will recover. The summer months will bring a decline, with prices fluctuating between $33 and $35. The situation will improve by the fall and end of the year, and the stock may again reach levels above $40, with possible spikes in November. Overall, there can be significant fluctuations in 2026, with eventual growth and correction periods.
| Month | Average price, $ | Minimum, $ | Maximum, $ |
|---|---|---|---|
| January | 38.16 | 35.55 | 40.05 |
| February | 40.74 | 39.79 | 43.67 |
| March | 41.40 | 39.31 | 42.26 |
| April | 40.17 | 37.96 | 42.63 |
| May | 36.55 | 34.22 | 38.69 |
| June | 35.57 | 33.81 | 37.62 |
| July | 34.09 | 32.28 | 34.80 |
| August | 33.30 | 32.01 | 34.85 |
| September | 35.36 | 33.58 | 36.51 |
| October | 38.52 | 36.92 | 39.28 |
| November | 41.70 | 39.98 | 43.73 |
| December | 39.45 | 37.39 | 42.01 |
Pfizer’s Stock Price Changes Over Time
Pfizer’s stock price journey, encapsulated over decades, showcases the dynamic interplay between company performance, market trends, and external factors. From a modest beginning in the late 1970s, the stock gradually grew, often mirroring broader market trends and Pfizer’s developments. The 1990s marked significant growth, attributed to successful drug launches and robust pharmaceutical industry trends. However, the early 2000s presented challenges, with stock fluctuations reflecting broader market uncertainties and specific concerns like patent expirations.
Critical influences on Pfizer’s stock include earnings reports, dividend announcements, and FDA approvals. The company’s financial performance, such as revenue and EPS, significantly impacts investor decisions. Pfizer’s role in developing treatments and vaccines also shapes market sentiment, reflecting the intricate relationship between company activities and stock performance.
What Will Pfizer Stock Be Worth in 2027-2030?
Based on CoinPriceForecast‘s data, Pfizer stock is expected to rise steadily from 2027 to 2030. In 2027, the average share price could be around $35.78 at mid-year, rising to around $36.91 by year-end. In 2028, the trend will continue, with the price rising to $38.17 at mid-year and $39.55 by year-end. In 2029, a more significant increase is projected, with the average price presumably reaching $42.30 at mid-year and $45.76 by year-end. In 2030, the trend remains positive, with the average price projected to hit $48.86. The year-end price could reach $49.42. Overall, this trend points to steady growth of Pfizer stock over the whole period.
| Year | Mid-Year, $ | Year-end, $ |
|---|---|---|
| 2027 | $35.78 | $36.91 |
| 2028 | $38.17 | $39.55 |
| 2029 | $42.30 | $45.76 |
| 2030 | $48.86 | $49.42 |
About the Pfizer Stock
Pfizer (NASDAQ: PFE) traces its origins to 1849, but it finally became a publicly-traded company in 1942, nearly a century after its founding. The $5.9 million IPO was one of the largest of that year, with shares valued at a price of $24.75 apiece. On the very first day, the company reached the market cap of $12.4 million.
At the time of its incorporation, the chemical enterprise was valued at $2 million. Today, the market cap has reached $215 billion, and it’s still one of the largest manufacturers and distributors of pharmaceuticals, agricultural and animal health products, pharmaceutical chemicals, nutritional products, and items for personal, household, and industrial use.
Currently, Pfizer is a component of the following U.S. stock market indices:
- S&P 500
- S&P 500 Health Care
- S&P 100
- Dow Jones Composite Average
- Dow Jones Industrial Average
Pfizer stock price for today (30.08.2024) is $28.72. You can refer back to this article to see Pfizer’s stock price tomorrow.
Main Factors That Drive Pfizer (PFE) in 2024 & in the Future
The company’s success hinges on its ability to adapt to various external factors that influence its operations and strategic decisions. Here are the main factors driving Pfizer:
- Political Factors: Government regulations, healthcare policies, intellectual property rights, and political stability significantly impact Pfizer’s business operations and profitability.
- Economic Factors: Global economic conditions, currency exchange rates, interest rates, and healthcare spending trends are crucial in shaping Pfizer’s financial performance.
- Sociocultural Factors: Demographic shifts, health consciousness, cultural attitudes towards medicine, and social movements influence consumer preferences and demand for Pfizer’s products.
- Technological Factors: Innovations in R&D, drug manufacturing technologies, and digital health trends are essential to Pfizer’s competitive edge and future growth.
- Environmental Factors: Waste management, sustainable resource use, and compliance with environmental regulations are vital for Pfizer’s operational efficiency and corporate responsibility.
- Legal Factors: Drug approval regulations, IP rights, litigation risks, and compliance with advertising and data protection laws are essential considerations for Pfizer’s legal and ethical operations.
Is Pfizer a Good Long-Term Investment?
Thanks to its success in developing COVID-19 vaccines and other pharmaceutical innovations, Pfizer has demonstrated significant profit growth and stable sales. However, shortly after the end of the epidemic, the company’s stocks began to decline rapidly. The lack of innovative patents and the company’s restructuring have affected the stock price. Wall Street analysts still hold a positive forecast, although it is now much more cautious.
Investors should note the risks inherent in the pharmaceutical industry, including regulatory challenges. However, Pfizer’s solid earnings per share (EPS), consistent dividend yield, and strategic R&D investments in immunology and therapeutics enhance its appeal.
FAQs on Pfizer Stock Forecast
The current price of Pfizer stock as of 30.08.2024 is at 28.72 US Dollars.
Analysts are skeptical about Pfizer’s short-term prospects, expecting the stock to remain in a sideways channel in the near time. However, long-term forecasts indicate growth potential due to the company’s robust product pipeline and innovative developments.
The future of Pfizer’s stock price looks promising due to its broad portfolio of drugs and treatments. The company will likely continue to strengthen its market position in the long term, which could positively impact its stock price. However, investors should be aware of market risks and volatility.
Pfizer shares could remain sideways in 2024 with a target of around $27 unless a significant change occurs by the end of the summer. Investors should consider potential risks, volatility, and possible dividends. Long-term prospects depend on drug development progress and external factors.
The Pfizer share price is projected to reach around $35 in 2025, although there are more pessimistic scenarios where the price could drop to around $24. This will depend on the success of new drug development and overall market conditions.
Predicting Pfizer’s stock price in 2030 is difficult, but conservative estimates suggest it could be worth around $45 if the company continues to grow and strengthen its market position. Still, much will depend on global economic conditions and the company’s success in innovation.
Pfizer shares are not low risk at this time, and their actual value may vary. It is recommended that new data and changes in the company be monitored to get a more accurate forecast and assess the investment potential before making decisions.
Pfizer stock is considered a good long-term investment due to its strong scientific potential, robust product pipeline, and stable market position. The company is actively investing in the development of new drugs, which may support its value growth in the future. However, investors should consider market risks and long-term volatility.
Price chart of PFE in real time mode
The content of this article reflects the author’s opinion and does not necessarily reflect the official position of LiteFinance. The material published on this page is provided for informational purposes only and should not be considered as the provision of investment advice for the purposes of Directive 2004/39/EC.
{{value}} ( {{count}} {{title}} )
This post is originally published on LITEFINANCE.
